Butorgesic 10 mg/ml solution for injection

Authorised

- Butorphanol tartrate
- Butorphanol tartrate
- Butorphanol tartrate
- Butorphanol tartrate

Product identification

Medicine name:
Butorgesic 10 mg/ml solution for injection

Active substance:
Butorphanol tartrate
Butorphanol tartrate
Butorphanol tartrate
Butorphanol tartrate

Target species:
Cat
Dog
Horse

Route of administration:
Intravenous use
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:

Butorphanol tartrate
14.58 milligram(s) / 1.00 millilitre(s)

Butorphanol tartrate
14.58 milligram(s) / 1.00 millilitre(s)

Butorphanol tartrate
14.58 milligram(s) / 1.00 millilitre(s)

Butorphanol tartrate
14.58 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intravenous use:

- **Horse**
  - Milk. 0 day
  - Milk. 0 day
  - Milk. 0 day
  - Milk. 0 day
  - Meat and offal. 0 day
  - Meat and offal. 0 day
  - Meat and offal. 0 day
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02AF01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:
Available only in Danish
Available only in Danish
Available only in Danish
Available only in Danish
Available only in Danish
Available only in Danish

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:
20/05/2021

Manufacturing sites for batch release:
CP-Pharma Handelsgesellschaft mbH

Responsible authority:
Danish Medicines Agency

Authorisation number:
63626

Date of authorisation status change:
20/05/2021

Reference member state:
Denmark

Procedure number:
DK/V/0124/001

Concerned member states:
Austria Finland France Hungary Italy Norway Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 25/01/2022
Download